Gilead Sciences, Inc. is committed to providing access to its HIV medicines to all patients who need them worldwide, regardless of income or geography. Gilead has developed a tiered pricing system for its HIV medicines, including Viread® (tenofovir disoproxil fumarate) and Truvada® (emtricitabine and tenofovir disoproxil fumarate), based on a country's economic status and HIV prevalence. It offers substantial price reductions through its Access Program in 130 countries, representing two-thirds of the countries in the world, and the regions hardest hit by the AIDS epidemic.

Gilead has established an international network of distributors, whose local knowledge helps to accelerate country-level regulatory approval of its medicines. These distributors also provide local outreach and on-the-ground logistics, and help ensure secure distribution of Gilead's HIV medicines in the developing world.